TransMedics Group, Inc. Q3 2025 Earnings Recap

TMDX Q3 2025 October 31, 2025

TransMedics achieved robust Q3 2025 results, with total revenue up 32.2% year-over-year to approximately $144 million, driven by strong growth across all organ segments despite typical seasonal slowdowns.

Earnings Per Share Beat

$0.66 vs $0.37 est.

+78.4% surprise

Revenue Miss

143823000 vs 155411000 est.

-7.5% surprise

Market Reaction

1-Day -3.13%

5-Day -8.34%

30-Day +7.52%

Key Takeaways

Operating profit soared to $23.3 million, representing over 16% of total revenue, compared to just 4% in Q3 2024.
Transplant logistics service revenue grew 35% year-over-year, with 21 aircraft currently operational to enhance mission coverage.
Anticipation builds for the upcoming ENHANCE Heart and DENOVO Lung clinical trials, expected to drive future adoption of OCS technology.
Expansion into international markets is underway, with plans to launch the first OUS NOP program in Italy and establish strategic regional hubs.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TMDX on AllInvestView.